PURPOSE OF REVIEW This article discusses the clinical presentation, evaluation, and
management of the patient with optic neuritis. Initial emphasis is placed on clinical history …

The use of magnetic resonance imaging as a surrogate outcome measure in clinical trials, or
even as a prognosticator in the assessment of the natural evolution, assumes a close …

Objective To characterize the accrual of long‐term disability in a cohort of actively treated
multiple sclerosis (MS) patients and to assess whether clinical and magnetic resonance …

Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease of the
central nervous system. It affects approximately 400,000 people in the United States and …

Abstract Information-processing speed (IPS) slowing is a primary cognitive deficit in multiple
sclerosis (MS). Basal ganglia, thalamus and neocortex are thought to have a key role for …

Objective: To assess the time course of brain atrophy and the difference across clinical
subtypes in multiple sclerosis (MS). Methods: The percent brain volume change (PBVC) was …

Objective To review evidence on starting, switching, and stopping disease-modifying
therapies (DMTs) for multiple sclerosis (MS) in clinically isolated syndrome (CIS), relapsing …

Brain atrophy has emerged as a clinically relevant component of disease progression in
multiple sclerosis. Progressive loss of brain tissue bulk can be detected in vivo in a sensitive …

Background Typical optic neuritis is often the presenting manifestation of multiple sclerosis
(MS). Its incidence in central Europe is 5 cases per 100 000 persons per year. Methods This …

Objectives To identify MRI biomarkers associated with long-term disability progression in
patients with multiple sclerosis (MS), and to define the rate of evolution of global, tissue …